Stock of interest

August 28, 2007

Neurochem Inc.

Shares declined $2.40 to $3.16 after the drug developer said a study of its Alzheimer's disease drug candidate Alzhemed did not show a statistically significant benefit, compared with a placebo.

Baltimore Sun Articles
|
|
|
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.